New journal hopes to capitalize on growing specialty pharmacy niche

Share this article:
New journal hopes to capitalize on growing specialty pharmacy niche
New journal hopes to capitalize on growing specialty pharmacy niche

Pharmacy Times launched a new title, Specialty Pharmacy Times, which will focus on policy, regulatory and legal issues, as well as product reviews, reimbursement and new clinical trends in specialty pharmacy.

“Current spending on specialty pharmaceuticals is estimated at more than $100 billion, with that figure expected to increase to $1.7 trillion in 2030," said Bill Schu, group editorial director, in an email. “Our audience needs to keep on top of key issues in the profession – clinical issues and issues from a practice and business point of view – and Specialty Pharmacy Times will fill that niche."

The journal's inaugural issue was unveiled at the Academy of Managed Care Pharmacy meeting in October, and copies will go out to qualified subscribers, gratis, said Tighe Blazier, president, Pharmacy Times. Qualified subscribers include corporate executives, reimbursement specialists and pharmacists, as well as pharmacy and formulary directors at managed care organizations and in government, among others.

Blazier said the journal hopes to attract pharmaceutical and biotech advertising clients that manufacture products and offer services that require specialized distribution channels. “They will be the main beneficiaries of this important new communication platform,” said Blazier. Specialty Pharmacy Times will also be supported by online advertising, and will begin sending out a bi-weekly e-newsletter “very soon,” per Blazier. An iPad version of the journal is also in the works.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...